Skip to main content


This website is provided to comply with patent marking provisions of various jurisdictions including the virtual patent provisions of 35 USC § 287(a) of the United States.

The CSL Behring products listed below are covered by one or more patents in the United States and/or other countries.  The patent information is believed to be accurate as of the Last Update.

The content of this list may change from time to time due to events including, but not limited to: filing, publication, issuance, licensing, product changes, expiration, abandonment, and other circumstances.  This list may not be inclusive of all patents covering a specific product in the US or elsewhere; and the absence of a specific product from the list does not indicate that the product is unpatented in the US or elsewhere.

Product Patents List

Privigen®  (Immune Globulin Intravenous (Human), 10% Liquid)
United States Patent Nos. 8,715,652; and 8,906,368.
Hizentra® (Immune Globulin Subcutaneous (Human), 20% Liquid)
United States Patent Nos. 8,715,652; 8,906,368; 9,422,364; and 10,434,176.
AFSTYLA® (Antihemophilic Factor (Recombinant) Single Chain)
United States Patent Nos. 7,041,635 (SK Bioscience Co. Ltd.); and 9,926,361 (SK Bioscience Co. Ltd.); and 10,537,616.
IDELVION® (Coagulation Factor IX (Recombinant) Albumin Fusion Protein)
United States Patent Nos. 7,939,632 and 10,080,785 (Novozymes Biopharma DK A/S).
HEMGENIX® ((etranacogene dezaparvovec-drlb) suspension, for intravenous infusion)
United States Patent Nos. 8,168,425 (St. Jude Children's Research Hospital); 8,030,065 (St. Jude Children's Research Hospital); 9,580,691 (uniQure IP B.V.); 10,190,098 (uniQure IP B.V.); 11,306,291 (uniQure IP B.V.); 8,697,417 (uniQure IP B.V.); and 9,249,405 (uniQure Biopharma B.V.)
Last updated: 20 January 2023